No Data
No Data
Fractyl Health (GUTS.US) GLP-1 gene therapy can prevent the rebound when stopping semaglutide.
Fractyl Health, which focuses on developing new methods for obesity and type 2 diabetes, reported the latest data on its preclinical GLP-1 gene therapy Rejuva at the 84th American Diabetes Association (ADA) Scientific Sessions.
BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
Express News | Fractyl: Expects Open Label Data From Reveal-1 Cohort in Q4,Mid-Point Analysis for Remain-1 in 2025
Express News | Fractyl Health: Will Accelerate Revita Weight Maintenance Clinical Study Remain-1
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
No Data